Darunavir.
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic responses superior to comparator-based regimens.
El-Atrouni
Wissam I
WI
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA.
Temesgen
Zelalem
Z
D002986:Clinical Trials as Topic; D000069454:Darunavir; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D000069454:Darunavir